Shylicine® [patent pending] is a cocktail that is developed with the ultimate goal of eliminating the need for TPN in Microvillus Inclusion Disease (MVID) patients.
Shylicine® reverses the imbalance of secretion and absorption caused by MVID and restores the appearance and the function of the intestinal mucosa. It is currently limited to investigational use only and is not available for sale.
March 08, 2022 – Hamden, Connecticut
Vanessa Biotech (VB) filed a patent application for the novel and promising treatment of inflammatory bowel disease on February 20 as a patent cooperation treaty countries (PCT) application, allowing to streamline the intellectual property (IP) protection process and to pursue IP protection in any and all of 155 member states of the treaty.
March 01, 2022 – Hamden, Connecticut
Vanessa Biotech (VB), proudly supported Rare Disease Day for the fifth consecutive year. Rare Disease Day is observed internationally each year on the last day of February, because that day is viewed as the rarest day of the year. The aim of the day is to raise awareness regarding the 300 million people worldwide who are battling rare diseases.
October 19, 2021 – Hamden, Connecticut
Ghana FDA grants final approval to Vanessa Biotech for Phase II clinical trials for VR-AD-1005, a novel antidiarrheal investigational drug, for treatment of severe diarrhea of cholera.The Phase 2 study will be conducted during the current rainy season by the University of Ghana’s research team lead by Prof. Ernest Kenu as Principal Investigator. The team had its kickoff meeting on August 12, 2021, and is now in full preparation mode for the trial to begin recruiting patients.